Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Active | ||
Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Reimburse with clinical criteria and/or conditions | Active | ||
Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Reimburse with clinical criteria and/or conditions | Active | ||
Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
Hemgenix | etranacogene dezaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
Livmarli | maralixibat | Alagille syndrome | Reimburse with clinical criteria and/or conditions | Active | ||
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Active | ||
Remsima | infliximab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Active |